Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DDO-2728
- Development stage
- Preclinical
- Lead developer
- China Pharmaceutical University
01
Overview
DDO-2728: sourced facts only. name: "We identified DDO-2728 as a novel and selective inhibitor of ALKBH5 by structure-based virtual screening and optimization." [PMID:37983486]; target: "We identified DDO-2728 as a novel and selective inhibitor of ALKBH5 by structure-based virtual screening and optimization." [PMID:37983486]; developer: "State Key Laboratory of Natural Medicines, and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China." [PMID:37983486]; stage: "Furthermore, DDO-2728 significantly suppressed tumor growth in the MV4-11 xenograft mouse model and showed a favorable safety profile." [PMID:37983486]
02
Targets
ALKBH5 (AlkB homolog 5, RNA demethylase)
Beyond the preview
Go deeper on DDO-2728.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DDO-2728.